TFA Therapeutics (RAJAF) Current Deferred Revenue (2025)
TFA Therapeutics (RAJAF) posted Current Deferred Revenue of $4912.0 for Q4 2025.
Powered by 
Analysis
TFA Therapeutics (RAJAF) Current Deferred Revenue (2025) Analysis & Trends
TFA Therapeutics has reported Current Deferred Revenue for 1 years, with the latest figure at $4912.0 in Q4 2025.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $4912.0 in Q4 2025; TTM through Dec 2025 was $4912.0, a N/A change from a year earlier, with the FY2025 full-year figure at $4912.0, changed N/A from the prior year.
- Current Deferred Revenue was $4912.0 for Q4 2025 at TFA Therapeutics.
- The five-year high for Current Deferred Revenue was $4912.0 in Q4 2025, with the low at $4912.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Colgate Palmolive | 70.36 Bn | 68.99 Bn | 3.30 Bn |
| 2 | Kenvue | 34.53 Bn | 33.42 Bn | 2.30 Bn |
| 3 | Kimberly Clark | 33.25 Bn | 32.30 Bn | 1.60 Bn |
| 4 | Bath & Body Works | 3.98 Bn | 3.19 Bn | 692.00 Mn |
| 5 | Prestige Consumer Healthcare | 2.37 Bn | 2.30 Bn | - |
| 6 | Perrigo | 2.01 Bn | 1.61 Bn | 313.90 Mn |
| 7 | Herbalife | 1.28 Bn | 911.72 Mn | 1.03 Bn |
| 8 | Edgewell Personal Care | 1.26 Bn | 866.04 Mn | 242.50 Mn |
| 9 | TFA Therapeutics | 1.02 Bn | 1.02 Bn | - |
| 10 | Honest Company | 620.00 Mn | 514.11 Mn | 40.36 Mn |